Barclays PLC Xencor Inc Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

A detailed history of Barclays PLC transactions in Xencor Inc stock. As of the latest transaction made, Barclays PLC holds 155,568 shares of XNCR stock, worth $3.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
155,568
Previous 155,568 -0.0%
Holding current value
$3.82 Million
Previous $3.13 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$15.7 - $21.65 $1.23 Million - $1.69 Million
78,066 Added 100.73%
155,568 $3.13 Million
Q2 2024

Aug 14, 2024
SELL
$18.21 - $24.5 $376,273 - $506,243
-20,663 Reduced 21.05%
77,502 $1.47 Million
Q1 2024

May 15, 2024
SELL
$18.65 - $26.52 $3.18 Million - $4.52 Million
-170,334 Reduced 63.44%
98,165 $2.17 Million
Q4 2023

Feb 15, 2024
BUY
$16.53 - $21.42 $2.7 Million - $3.5 Million
163,582 Added 155.92%
268,499 $5.7 Million
Q3 2023

Nov 07, 2023
BUY
$20.08 - $25.39 $351,962 - $445,035
17,528 Added 20.06%
104,917 $2.12 Million
Q2 2023

Aug 03, 2023
BUY
$24.77 - $29.9 $361,419 - $436,270
14,591 Added 20.04%
87,389 $2.18 Million
Q1 2023

May 04, 2023
SELL
$25.95 - $36.95 $468,631 - $667,280
-18,059 Reduced 19.88%
72,798 $2.03 Million
Q4 2022

Feb 13, 2023
BUY
$24.79 - $30.86 $123,379 - $153,590
4,977 Added 5.8%
90,857 $2.37 Million
Q3 2022

Nov 03, 2022
BUY
$24.62 - $32.44 $1.66 Million - $2.19 Million
67,447 Added 365.9%
85,880 $2.23 Million
Q2 2022

Aug 12, 2022
SELL
$19.74 - $29.01 $574,216 - $843,871
-29,089 Reduced 61.21%
18,433 $505,000
Q1 2022

May 16, 2022
SELL
$26.68 - $41.63 $706,593 - $1.1 Million
-26,484 Reduced 35.79%
47,522 $1.27 Million
Q4 2021

Feb 14, 2022
BUY
$33.67 - $43.44 $745,824 - $962,239
22,151 Added 42.72%
74,006 $2.97 Million
Q3 2021

Nov 09, 2021
BUY
$30.65 - $35.68 $295,220 - $343,669
9,632 Added 22.81%
51,855 $1.69 Million
Q2 2021

Aug 13, 2021
SELL
$34.33 - $44.68 $1.13 Million - $1.47 Million
-32,911 Reduced 43.8%
42,223 $1.46 Million
Q1 2021

May 13, 2021
BUY
$40.81 - $53.88 $290,648 - $383,733
7,122 Added 10.47%
75,134 $3.24 Million
Q4 2020

Feb 11, 2021
SELL
$36.63 - $47.63 $2.29 Million - $2.98 Million
-62,471 Reduced 47.88%
68,012 $2.97 Million
Q3 2020

Nov 12, 2020
BUY
$30.09 - $43.02 $1.91 Million - $2.73 Million
63,346 Added 94.35%
130,483 $5.06 Million
Q2 2020

Aug 12, 2020
SELL
$27.76 - $33.42 $144,823 - $174,352
-5,217 Reduced 7.21%
67,137 $2.18 Million
Q1 2020

May 13, 2020
SELL
$20.69 - $37.79 $323,136 - $590,204
-15,618 Reduced 17.75%
72,354 $2.16 Million
Q4 2019

Feb 10, 2020
BUY
$32.75 - $41.43 $1.11 Million - $1.4 Million
33,829 Added 62.48%
87,972 $3.03 Million
Q3 2019

Nov 14, 2019
BUY
$33.73 - $46.27 $790,597 - $1.08 Million
23,439 Added 76.34%
54,143 $1.83 Million
Q2 2019

Aug 14, 2019
BUY
$29.6 - $40.93 $518,000 - $716,275
17,500 Added 132.54%
30,704 $1.26 Million
Q1 2019

May 15, 2019
BUY
$27.85 - $38.09 $367,731 - $502,940
13,204 New
13,204 $410,000
Q4 2018

Feb 14, 2019
SELL
$32.39 - $42.05 $1.06 Million - $1.38 Million
-32,770 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$35.69 - $47.65 $702,593 - $938,037
19,686 Added 150.46%
32,770 $1.28 Million
Q2 2018

Aug 14, 2018
BUY
$28.41 - $42.41 $117,162 - $174,898
4,124 Added 46.03%
13,084 $484,000
Q1 2018

May 15, 2018
BUY
$21.18 - $33.78 $53,331 - $85,058
2,518 Added 39.09%
8,960 $269,000
Q4 2017

Feb 14, 2018
BUY
$19.29 - $24.83 $45,755 - $58,896
2,372 Added 58.28%
6,442 $141,000
Q3 2017

Nov 14, 2017
BUY
$19.61 - $23.35 $79,812 - $95,034
4,070
4,070 $94,000

Others Institutions Holding XNCR

# of Institutions
215
Shares Held
71.5M
Call Options Held
2.5K
Put Options Held
7.9K
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.47B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email